Current advances in Hodgkin’s lymphoma
Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has r...
Guardado en:
Autores principales: | Joseph Vadakara, Benjamin Andrick |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/581c062dee694a08ac01bdf0eca28236 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Beate Hauptrock, et al.
Publicado: (2008) -
Unusual presentation of a clinically isolated temporal region mass: Non‐Hodgkin lymphoma
por: Mariam Mella, et al.
Publicado: (2021) -
EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED HODGKIN’S LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT
por: Jhanzeb Iftikhar, et al.
Publicado: (2021) -
Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
por: Pierre Pinochet, et al.
Publicado: (2021) -
Massive pericardial effusion as the first manifestation of childhood non‐Hodgkin's lymphoma: A case report
por: Behzad Alizadeh, et al.
Publicado: (2021)